# A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

> **NCT06801223** · PHASE1 · RECRUITING · sponsor: **Innoviva Specialty Therapeutics** · enrollment: 48 (estimated)

## Conditions studied

- Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)

## Interventions

- **DRUG:** Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)
- **DRUG:** Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)
- **DRUG:** Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)
- **DRUG:** Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)

## Key facts

- **NCT ID:** NCT06801223
- **Lead sponsor:** Innoviva Specialty Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-30
- **Primary completion:** 2028-05-05
- **Final completion:** 2028-05-20
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06801223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06801223, "A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06801223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*